NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
AbbVie
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SUNHO(China)BioPharmaceutical CO., Ltd.